Merck, a science and technology company, agreed to acquire Chord Therapeutics, a biopharmaceutical company, from Omega Funds, an international investment firm that creates and invests in life sciences companies. "I am very pleased with Chord's progress over the last year since our launch. I am grateful to Omega Funds for their support and financing, and for sharing our vision of the potential of cladribine in NMOSD and gMG. We are thrilled that our work is now continued by Merck and delighted with this opportunity to considerably accelerate the development to bring this drug to patients in need faster," Tom Plitz, Chord Therapeutics CEO.